CAR-T cell therapy represents a revolutionary immunotherapy for relapsed and refractory blood cancers, now accessible in India at dramatically reduced costs compared to international prices, offering new hope to patients who have exhausted conventional treatment options. TL;DR India's CAR-T cell therapy costs ₹30-50 lakhs compared to ₹3-4 crores internationally, representing an 80-90% cost reduction for blood cancer patients [3] Indigenous therapies like NexCAR19 demonstrate